B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel downgraded X4 Pharmaceuticals (XFOR) from Buy to Neutral and reduced the price target from $3 to $1.
December 12, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
X4 Pharmaceuticals was downgraded by B. Riley Securities from Buy to Neutral with a price target decrease from $3 to $1.
The downgrade by a prominent analyst and the significant reduction in price target are likely to negatively impact investor sentiment and could lead to a short-term decline in XFOR's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100